Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion. - The Arthritis Research UK Centre...
We aimed to characterize incident users of alendronate from Denmark and Spain, and investigate their eligibility for participation in the pivotal Fracture Intervention Trial (FIT). This is an international cross-sectional study, where the data were obtained from the SIDIAP database (Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària) from Catalonia (Spain) and the Danish Health Registries (DHR). This study included patients who were incident users of alendronate, ≥40 years old with no history of Paget's disease. Our measurements were the proportion of incident users of alendronate who were not eligible to participate in FIT. 14,316 and 21,221 subjects initiated alendronate in 2006-2007 (SIDIAP) and 2005-2006 (DHR), respectively. SIDIAP and DHR alendronate user cohorts had 2347 (16.4 %) and 5275 (24.9 %) subjects aged |80 years old, reported 9 (0.1 %) and 91 (0.4 %) diagnoses of myocardial ...https://oacentre.kennedy.ox.ac.uk/publications/617690
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial....
BACKGROUND: Preventing bone loss associated with menopause and aging and maintaining the normal micro-architecture of bone provide important opportunities for the prevention of osteoporosis and fractures. OBJECTIVE: To determine the safety and efficacy of alendronate, an aminobisphosphonate, for preventing postmenopausal bone loss. DESIGN: 3-year double-blind, randomized, placebo-controlled trial. SETTING: 15 osteoporosis centers throughout the world. PARTICIPANTS: 447 women who had recently experienced menopause (6 to 36 months before study entry). INTERVENTION: Participants were randomly assigned to one of five regimens: oral placebo; oral alendronate, 1, 5, or 10 mg/d; or oral alendronate, 20 mg/d for 2 years followed by placebo during the third year (20/0 mg/d). MEASUREMENTS: Bone mineral density was ...https://www.garvan.org.au/research/publications/1206
Alendronate and/or Parathyroid Hormone for Osteoporosis - Full Text View - ClinicalTrials.gov
This is a randomized, prospective, open-label study in which osteoporotic postmenopausal women self-administer synthetic hPTH-(1-34), alendronate, or both, every day for 2.5 years. Participants initially come to Massachusetts General Hospital once a month, and subsequently once every 3-6 months, for measurements of serum and urine indices of bone formation and resorption, serum and urine toxicity tests, and DXA/QCT measurements of bone mass. One-third of the participants take hPTH-(1-34) daily, one-third take alendronate once daily, and one-third take both daily (Phase A, months 0-30).. Participants who complete Phase A are eligible for a 12 month extension study (Phase B, months 30-42), during which any alendronate treatment is continued without change and any hPTH 1-34 treatment is stopped.. Participants who complete Phase B are eligible for a second 12 month extension ...https://clinicaltrials.gov/ct2/show/NCT00000400?term=
Proton-pump inhibitors were associated with reduced effectiveness of alendronate for preventing hip fractures
The Effect of Alendronate on Fracture-Related Healthcare Utilization and Costs: The Fracture Intervention Trial. Chrischilles, E. A.; Dasbach, E. J.; Rubenstein, L. M.; Cook, J. R.; Tabor, H. K.; Black, D. M. // Osteoporosis International;Sep2001, Vol. 12 Issue 8, p654 The Vertebral Fracture Arm (VFA) of the Fracture Intervention Trial (FIT) study demonstrated that alendronate reduced the incidence of spine, forearm and hip fractures in women with low bone mass and existing vertebral fractures by about 50%. The objective of the present study was to determine... ...http://connection.ebscohost.com/c/articles/69859261/proton-pump-inhibitors-were-associated-reduced-effectiveness-alendronate-preventing-hip-fractures
A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253) -...
This study will evaluate the bioequivalence of alendronate in combination with vitamin D compared to alendronate alone and the bioequivalence of vitamin D in combination with alendronate compared to vitamin D alone.. This was an open-label, randomized, 2-part, crossover study. Each participant participated in one part of the study only (i.e., each participant participated only in Part I or only in Part II). Participants entered the study sequentially within each part of the study. A washout of at least 12 days separated each treatment period within each part of the study. ...https://clinicaltrials.gov/ct2/show/record/NCT00803790
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal...
UNLABELLED Once-weekly alendronate 70 mg and once-weekly risedronate 35 mg are indicated for the treatment of postmenopausal osteoporosis. These two agents were compared in a 12-month head-to-head trial. Greater gains in BMD and greater reductions in markers of bone turnover were seen with alendronate compared with risedronate with similar tolerability. INTRODUCTION The nitrogen-containing bisphosphonates, alendronate and risedronate, are available in once-weekly (OW) formulations for the treatment of postmenopausal osteoporosis. A 12-month, head-to-head study was performed to compare these agents in the treatment of postmenopausal women with low BMD. MATERIALS AND METHODS A total of 1053 patients from 78 U.S. sites were randomized to OW alendronate 70 mg (N = 520) or risedronate 35 mg (N = 533), taken in the morning after fasting. Endpoints included BMD changes over 6 and 12 months at the hip ...https://www.semanticscholar.org/paper/Treatment-with-once-weekly-alendronate-70-mg-compa-Rosen-Hochberg/2821fa5d0e4a54e2c39b06e2e1a81c2c659e0281
Synthesis, Biological Evaluation and Molecular Docking Studies of High-Affinity Bone Targeting N,N'-Bis (alendronate)...
A bisphosphonate derivative DTPA-bis(alendronate) conjugate has been synthesized and evaluated as potential radiopharmaceutical for bone imaging. The compound was synthesized by the covalent coupling of DTPA-bis(anhydride) with alendronate and was char-acterized on the basis of IR, NMR and mass spectroscopy. It was labelled with 99mTc with 96% efficacy and was found stable for about 24 h under physiological conditions. Blood kinetic studies of 99mTc DTPA-bis(alendronate) showed a biexponential pattern as well as quick washout from the blood circulation. The biological t1/2(F) and t1/2(S) were found to be 50 min ± 0.001 and 6 h 30 min ± 0.005, respectively. Imaging and biodistribution studies showed a significant accumulation of 99mTc DTPA-bis(alendronate) conjugate at bone site. Bone-to-muscles ratios were 12.08 ± 0.001 at 1 h, 45.33 ± 0.001 ...http://onlinelibrary.wiley.com/doi/10.1111/cbdd.12194/abstract
Alendronate (Oral Route) Before Using - Mayo Clinic
If you are using alendronate oral liquid, drink at least 2 ounces (a quarter of a cup) of water immediately after taking the medicine. This will allow the medicine to reach your intestines and be absorbed by the body more quickly. Swallow the tablet whole with a full glass (6 to 8 ounces) of plain water. Do not suck or chew on the tablet because it may cause throat irritation. If you are taking alendronate effervescent tablet, dissolve it in 4 ounces of room temperature plain water only (not mineral water or flavored water). Wait at least 5 minutes after the effervescence stops and then stir the solution for 10 seconds and drink it. Do not lie down for at least 30 minutes after taking alendronate and before having your first food for the day. This will help alendronate reach your stomach faster. It will also help prevent irritation to your esophagus. It is important that you eat a well-balanced diet with adequate amounts of ...https://www.mayoclinic.org/drugs-supplements/alendronate-oral-route/before-using/DRG-20061571?p=1
DiVA - Søkeresultat
Importance Oral glucocorticoid treatment increases fracture risk, and evidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older patients using glucocorticoids.Objective To investigate whether alendronate treatment in older patients using oral prednisolone is associated with decreased hip fracture risk and adverse effects.Design, Setting, and Participants Retrospective cohort study using a national database (N = 433 195) of patients aged 65 years or older undergoing a health evaluation (baseline) at Swedish health care facilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone treatment (≥5 mg/d) were identified. Propensity score matching was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone with the same dose and treatment time criteria. Follow-up occurred between January 2008 and December 2014.Exposures ...http://www.diva-portal.org/smash/resultList.jsf?dswid=-666&searchType=SUBJECT&language=no&onlyFullText=false&af=%5B%5D&aq=%5B%5B%7B%22categoryId%22%3A%2211673%22%7D%5D%5D
Proton-pump inhibitors were associated with reduced effectiveness of alendronate for preventing hip fractures | Annals of...
Main results. 18% of patients used PPIs at baseline, and 27% used PPIs concurrently with alendronate during follow-up. 5.4% of patients had hip fractures, 1.5% had forearm fractures, 0.9% had humerus fractures, and 0.6% had spine fractures. Concurrent use of PPIs was associated with reduced effectiveness of alendronate for preventing hip fractures compared with no PPI use (Table); PPI use did not attenuate the effectiveness of alendronate for preventing forearm (4.5/1000 patient-y in PPI users vs 4.3/1000 patient-y in nonusers), humerus (2.9 vs 2.5/1000 patient-y), or spine (2.7 vs 1.3/1000 patient-y) fractures. In patients who used PPIs concurrently with alendronate, reduction in risk for hip fractures attenuated in a dose-dependent manner and was maintained only at lower cumulative PPI doses (cumulative defined daily doses [DDDs] 1 to 359, n = 7210, hazard ratio [HR] 0.63, 95% CI 0.55 to 0.72; DDDs 360 to 719, n = 1701, HR 1.00, CI 0.70 to ...http://annals.org/aim/article-abstract/1033129/proton-pump-inhibitors-were-associated-reduced-effectiveness-alendronate-preventing-hip
Alendronate by Sorres - Pharmasave
Atypical femur fracture: There is evidence that long term use of this class of medication may contribute to a type of rare fracture of the long bone in the thigh (femur).. If you experience new or unusual pain in the groin, hip, or thigh area, contact your doctor as soon as possible.. Bone, joint, and muscle problems: Rarely, people taking this medication experience severe bone, joint, or muscle pain. This is usually reversed when the medication is stopped.. Calcium and vitamin D: Calcium and vitamin D are important contributors to bone growth and strength. It may be necessary to take calcium or vitamin D supplements to get the best effect from alendronate if you are not getting enough from your diet. Your doctor may test you for low calcium levels or vitamin D deficiency before you start taking alendronate.. Effects on the esophagus: ...http://www.pharmasave.com/medications/alendronate-by-sorres/
Alendronate Sodium Hainan - Drugs.com
Alendronate Sodium Hainan is a medicine available in a number of countries worldwide. A list of US medications equivalent to Alendronate Sodium Hainan is available on the Drugs.com website.https://www.drugs.com/international/alendronate-sodium-hainan.html
Sandoz Alendronate - Uses, Side Effects, Interactions - Canada.com
Sandoz Alendronate: Alendronate belongs to a family of medications known as bisphosphonates. It is used to treat and prevent osteoporosis for postmenopausal women. It is also used to treat osteoporosis for men.http://bodyandhealth.canada.com/drug/getdrug/sandoz-alendronate
Effects of short-term combined treatment with alendronate and elcatoni | TCRM
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis Jun Iwamoto1, Mitsuyoshi Uzawa2, Yoshihiro Sato3, Tsuyoshi Takeda1, Hideo Matsumoto11Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan; 3Department of Neurology, Mitate Hospital, Fukuoka, Japan Abstract: The antiresorptive drug elcatonin (ECT) is known to relieve pain in postmenopausal women with osteoporosis. A prospective open-labeled trial was conducted to compare the effects of short-term combined treatment with alendronate (ALN) and ECT on bone mineral density (BMD) and bone turnover with those of single treatment with ALN in ...https://www.dovepress.com/effects-of-short-term-combined-treatment-with-alendronate-and-elcatoni-peer-reviewed-article-TCRM
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National...
In this Danish national register-based cohort study, we examined the effects of alendronate on the development of colon cancers and survival. The incidence of colon cancer and mortality rate, once colon cancer had been diagnosed, were lower in patients treated with alendronate, posing the question whether alendronate acts as chemopreventive.When bisphosphonates are given by mouth, around 99% remains non-absorbed in the intestine. Based on their biochemical actions, we predicted that oral bisphosphonates might prevent colon cancers.This is a Danish national register-based cohort study. We identified 30,606 women aged 50+, mean age 71.9 years, who had not previously taken treatments for osteoporosis, who began to take alendronate in 1996-2005, and assigned 124,424 individually age- and gender-matched control subjects. The main outcome measure was colorectal cancers incidence and post-diagnosis survival in patients taking oral ...https://www.ndorms.ox.ac.uk/publications/360179
Alendronate sodium / alendronate sodium NDA 076184 international drug patent coverage, generic alternatives and manufacturers
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...https://www.drugpatentwatch.com/p/NDA/076184
Alendronate sodium / alendronate sodium NDA 078638 international drug patent coverage, generic alternatives and manufacturers
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...https://www.drugpatentwatch.com/p/NDA/078638
Journal of Dental School Shahid Beheshti University of Medical Sciences
p,,strong,Background and Aim:,/strong, Chemotherapeutic agents are adjunctive substances for treatment of periodontitis through modulation of host response. Sodium alendronate is one of the medicaments which are used for this purpose. Since alkaline phosphates (ALP) level is an indicator for evaluation of bone metabolism changes, in this study the effect of sodium alendronate on periodontitis is investigated by measuring gingival crevicular fluid alkaline phosphates (GCF ALP) levels. ,/p,,p,,strong,Materials & Methods:,/strong, In this double-blind experimental study, 24 patients (12 males and 12 females between the agen of 35 to 50 years) with moderate chronic periodontitis have been evaluated. All patients received scaling and root planning. Sodium alendronate and placebo capsules were used weekly in a period of six months for case and control groups respectively samples were collected in first visit, 3 ...http://jds.sbmu.ac.ir/rss_mag.php?slc_lang=en&sid=1&mag_id=48
True Strength - Weinstein - 2010 - Journal of Bone and Mineral Research - Wiley Online Library
Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443 ...http://onlinelibrary.wiley.com/doi/10.1359/jbmr.2000.15.4.621/references
Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents - Full Text View -...
Puberty is a time when the foundation is laid for healthy bone mass. Over the course of puberty, 26% of bone mass is established in the 4-year period of peak height velocity and up to 60% of adult peak bone mass is established. Factors that affect normal bone mineralization include calcium intake, vitamin D status, degree of physical and weight bearing activities, hormones, genetics, body weight, and general health and nutrition status. HIV-infected children, youth, and adults have lower bone mineral density (BMD) than would be expected for healthy people of similar age, weight, and race. As the majority of perinatally HIV-infected U.S. children are entering or in adolescence, the potential for HIV-related impaired BMD during the adolescent peak of bone mass acquisition is ...https://clinicaltrials.gov/ct2/show/NCT00921557?recr=Open&cond=%22Bone+Density%22&rank=8
alendronate and cholecalciferol | PeaceHealth
Alendronate is in the group of medicines called bisphosphonates (bis FOS fo nayts). It alters the cycle of bone formation and breakdown in the body. Alendronate slows bone loss while increasing bone mass, which may prevent bone fractures. Cholecalciferol is a form of vitamin D, and is important for the absorption of...https://www.peacehealth.org/medical-topics/content/multum/d05526a1.html
Fonat Plus (alendronate sodium and colecalciferol) Drug / Medicine Information
Consumer Medicine Information (CMI) about Fonat Plus (alendronate sodium and colecalciferol) intended for persons living in Australia.https://www.news-medical.net/drugs/Fonat-Plus.aspx
What Is Alendronate and Cholecalciferol Used For?
Alendronate and cholecalciferol is used for the treatment of osteoporosis in men and postmenopausal women. This eMedTV article describes the effects of the drug and discusses possible off-label alendronate and cholecalciferol uses.http://senior-health.emedtv.com/alendronate-and-cholecalciferol/what-is-alendronate-and-cholecalciferol-used-for-p2.html
Buy Alendronate Without Prescription | Alendronate Online Pharmacy
Buy Alendronate 70mg, 35mg, 10mg, 5mg online without prescription in USA, Canada, Australia, UK and Europe. Fast order delivery. Worldwide shipping. FDA approved RX online pharmacy.http://www.tranect.co.uk/wp-content/uploads/2017/02/pharmacy/alendronate.html
Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate), an antiosteolytic agent, is currently under investigation in the treatment of a variety of bone diseases. Earlier studies from this laboratory have demonstrated that systemically administered alendronate is rapidly either taken up by bone tissues or excreted by the kidney, and that renal excretion is the only route of elimination. The purpose of this study is to characterize the renal handling of alendronate in rats by standard clearance procedures with inulin as a marker of glomerular filtration rate. Alendronate is highly bound to rat serum protein. The excretion of alendronate by the kidney is concentration-and dose-dependent, and saturable, indicating that it is secreted by an active transport mechanism. The secretory mechanism exhibits limitation of transport, with an apparent Tm of ...http://dmd.aspetjournals.org/content/20/4/608